A non-invasive prenatal test (NIPT) can detect the most common chromosomal abnormalities (trisomies 21, 18, and 13, and depending on the test method, sex chromosome aneuploidies as well as certain microdeletions) through modern high-throughput methods (next generation sequencing, NGS) performed on cell-free DNA of placental origin. This DNA is present in maternal blood or plasma during pregnancy. This significantly reduces the low procedural risk associated with invasive prenatal diagnostics for these specific questions. However, positive results should always be confirmed by amniocentesis, as false-positive and false-negative results are possible due to, for example, fetoplacental mosaicism.
All test methods require a sufficiently high fraction of placental DNA against the background of maternal DNA. The fetal fraction increases as pregnancy progresses but can be very low (< 4%) in some pregnant individuals. To ensure a sufficiently high fetal fraction for most individuals being tested, blood collection should not occur before the 10th week of pregnancy.
The tests currently available in Germany have been validated on high-risk populations, such as those with advanced maternal age or abnormal first-trimester screening results. For individuals without increased risk (e.g., pregnant individuals with unremarkable family histories or younger pregnant individuals), there is currently a lack of reliable data. Despite high sensitivity and specificity, false-positive and false-negative results can occur, which is why these tests are not currently considered diagnostic. Therefore, it is recommended that any abnormal findings be confirmed through diagnostic amniocentesis.
After genetic counseling (NIPT is regulated under the Genetic Diagnostics Act), 10-20 ml of blood are collected from the pregnant individual using specialized BCT tubes. After separating the blood plasma, the cell-free DNA from the placenta and mother is enriched and then quantitatively and/or qualitatively analyzed using NGS.
WAYS TO PARTNER WITH US
TarCET IVD Kits
CE-IVD kits containing reagents
for hereditary indications in
an easy-to-use kit form
Technology Transfer
Out-of-the-box genetics workflow
from sequencing to reporting
for non-invasive prenatal testing
Contact Us
Please get in touch with us
for any questions, inquiries,
feedback, or with any
comments you might have.
BLOG ARTICLES
The endometrial microbiome is increasingly recognized as a factor in reproductive health, and imbalances in microbial composition have been linked to…
Spinal muscular atrophy is a rare genetic condition that weakens muscles by affecting the motor nerve cells in the spinal cord. It is a leading genet…
Summer encourages people to spend more time outdoors, soaking in the sun and enjoying the season’s warm weather. While sunlight can have beneficial…
We’re thrilled to share the results of Medicover Genetics essay competition for high school students as well as the two winning essays. This competit…
Cystic fibrosis (CF) is a life-threatening, progressive, inherited condition that causes severe damage to the body, primarily affecting the organs of…
Down syndrome is a genetic condition caused by the presence of an extra copy of chromosome 21. It affects physical growth, facial features, and cogni…
Every year on April 25th, DNA Day celebrates the discovery of DNA’s double helix and the advances we’ve made in understanding genetics. D…
Neurodevelopmental disorders (NDDs) have diverse genetic origins, making diagnosis challenging. A new study analyzing over 1,100 pediatric patients f…
Colorectal cancer (CRC) remains one of the most prevalent and deadly cancers worldwide, with a significant number of cases presenting at an advanced …
Carrier screening is a genetic test designed to identify whether an individual carries a gene with changes (mutations) associated with inherited diso…
